The FDA has granted marketing clearance for ViewRay Inc’s radiotherapy treatment planning and delivery software. The solution is a component of the company’s new nonhuman-use research radiation therapy system, which combines simultaneous magnetic resonance imaging and radiotherapy delivery. The MRI system is designed to provide continuous soft-tissue MRI during cancer treatment.

ViewRay recently secured $20 million in series C financing to move the MRI system through the final development and regulatory processes, and toward the goal of commercialization and placement in major medical centers.